Display options
Cite
Yoo MY, Paeng JC, Cheon GJ, et al. Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma. Nucl Med Mol Imaging. 2015;49(4):291-7doi: 10.1007/s13139-015-0362-0.
Yoo, M. Y., Paeng, J. C., Cheon, G. J., Lee, D. S., Chung, J. K., Kim, E. E., & Kang, K. W. (2015). Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma. Nuclear medicine and molecular imaging, 49(4), 291-7. https://doi.org/10.1007/s13139-015-0362-0
Yoo, Min Young, et al. "Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma." Nuclear medicine and molecular imaging vol. 49,4 (2015): 291-7. doi: https://doi.org/10.1007/s13139-015-0362-0
Yoo MY, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE, Kang KW. Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma. Nucl Med Mol Imaging. 2015 Dec;49(4):291-7. doi: 10.1007/s13139-015-0362-0. Epub 2015 Aug 29. PMID: 26550048; PMCID: PMC4630329.
Copy Download .nbib Format: NLM
Share it on

Nucl Med Mol Imaging. 2015 Dec;49(4):291-7. doi: 10.1007/s13139-015-0362-0. Epub 2015 Aug 29.

Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma.

Nuclear medicine and molecular imaging

Min Young Yoo, Jin Chul Paeng, Gi Jeong Cheon, Dong Soo Lee, June-Key Chung, E Edmund Kim, Keon Wook Kang

Affiliations

  1. Department of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744 Korea.
  2. Department of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744 Korea ; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  3. Department of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744 Korea ; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
  4. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea ; Department of Radiological Sciences, University of California, Irvine, CA USA.

PMID: 26550048 PMCID: PMC4630329 DOI: 10.1007/s13139-015-0362-0

Abstract

PURPOSE: C-11 methionine (MET) PET is commonly used for diagnosing high-grade glioma (HGG). Recently, volumetric analysis has been widely applied to oncologic PET imaging. In this study, we investigated the prognostic value of metabolic tumor volume (MTV) on MET PET in HGG.

METHODS: A total of 30 patients with anaplastic astrocytoma (n = 12) and glioblastoma multiforme (n = 18) who underwent MET PET before treatment (surgery followed by chemo-radiotherapy) were retrospectively enrolled. Maximal tumor-to-normal brain ratio (TNRmax, maximum tumor activity divided by mean of normal tissue) and MTV (volume of tumor tissue that shows uptake >1.3-fold of mean uptake in normal tissue) were measured on MET PET. Adult patients were classified into two subgroups according to Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) classification. Prognostic values of TNRmax, MTV and clinicopathologic factors were evaluated with regard to progression-free survival (PFS).

RESULTS: Median PFS of all patients was 7.9 months (range 1.0-53.8 months). In univariate analysis, MTV (cutoff 35 cm(3)) was a significant prognostic factor for PFS (P = 0.01), whereas TNRmax (cutoff 3.3) and RTOG RPA class were not (P = 0.80 and 0.61, respectively). Treatment of surgical resection exhibited a borderline significance (P = 0.06). In multivariate analysis, MTV was the only independent prognostic factor for PFS (P = 0.03).

CONCLUSION: MTV on MET PET is a significant and independent prognostic factor for PFS in HGG patients, whereas TNRmax is not. Thus, performing volumetric analysis of MET PET is recommended in HGG for better prognostication.

Keywords: C-11 methionine; High-grade glioma; PET; Prognosis; Volumetric analysis

References

  1. Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1071-80 - PubMed
  2. Clin Cancer Res. 2004 Nov 1;10(21):7163-70 - PubMed
  3. J Clin Oncol. 2009 Dec 1;27(34):5743-50 - PubMed
  4. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):84-92 - PubMed
  5. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):241-51 - PubMed
  6. J Neurooncol. 2010 Jan;96(2):231-9 - PubMed
  7. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1247-56 - PubMed
  8. Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):52-9 - PubMed
  9. Mol Imaging. 2012 Nov-Dec;11(6):516-27 - PubMed
  10. Neurosurgery. 2009 Mar;64(3):471-81; discussion 481 - PubMed
  11. Nucl Med Mol Imaging. 2013 Mar;47(1):36-43 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74 - PubMed
  13. J Neurooncol. 2010 Sep;99(2):217-25 - PubMed
  14. Cancers (Basel). 2012 Mar 01;4(1):244-56 - PubMed
  15. Eur J Radiol. 2014 Jan;83(1):231-5 - PubMed
  16. AJNR Am J Neuroradiol. 2008 Jun;29(6):1176-82 - PubMed
  17. J Neurosurg. 2001 Nov;95(5):746-50 - PubMed
  18. Mol Imaging Biol. 2008 Jan-Feb;10(1):1-18 - PubMed
  19. Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101 - PubMed
  20. Neuro Oncol. 2004 Jul;6(3):227-35 - PubMed
  21. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007415 - PubMed
  22. J Neurooncol. 2011 Aug;104(1):339-49 - PubMed
  23. J Neurol Sci. 2006 Jul 15;246(1-2):85-94 - PubMed
  24. J Neurooncol. 2010 Sep;99(2):209-15 - PubMed
  25. J Nucl Med. 1998 May;39(5):778-85 - PubMed
  26. J Neurosurg. 2003 Sep;99(3):467-73 - PubMed
  27. AJNR Am J Neuroradiol. 2006 Aug;27(7):1432-7 - PubMed
  28. J Neurosurg. 2001 Aug;95(2):190-8 - PubMed

Publication Types